Burgdorf - Ypsomed (SIX: YPSN) will expand its offering of digital health solutions together with S3 Connected Health in the future. S3 Connected Health, headquartered in Dublin, Ireland is a specialist digital health partner for life science companies. The new offering will allow Ypsomed's biopharma customers to quickly launch therapy-specific digital patient solutions. People with acute and chronic diseases can thus be supported fully in their therapy management and the outcome of their treatment can be enhanced.
//// Ypsomed partners with S3 Connected Health to expand its digital health offering
Digital health solutions play an increasingly important role in how well patients with acute and chronic diseases manage their therapy. To further drive this development Ypsomed partners with S3 Connected Health to create an extendable platform for the creation of specific solutions that provide patients with support and guidance throughout their therapy. Ypsomed's connected injection devices such as the SmartPilot for YpsoMate are pre-integrated in the platform. The platform is highly versatile and quick to customize for any disease area and use case - always with the aim to provide additional value to patients.
The new platform will enable our Pharma and Biotech customers to rapidly launch integrated device and digital health solutions that will further improve therapy outcomes and quality of life for their patients. This new product offering complements our existing product portfolio and partnerships in the connected device and digital health area. It will help us to strengthen our position in this space and provide our customers with the best possible value,
explains Ulrike Bauer, Chief Business Officer Delivery Systems.
Less complexity with higher added value
Ypsomed's offering is powered by S3 Connected Health's Affinial Platform, the most comprehensive platform for life science companies to create regulated digital health solutions. Affinial is designed to power digital health applications and use cases by encoding over 20 years' experience of best practice in delivery of digital health at scale. Since Affinial was launched it has established itself as the leading platform for life sciences companies.
The new platform offering includes a patient application, a clinical system, a Patient Support Portal (PSP portal) and analytical dashboard with real-time access to anonymized data. Alongside pre-integration of Ypsomed's device portfolio, the platform provides a range of features around self-injection, incorporates behavioral science mechanisms to ensure high levels of engagement, and personalization of the application to users' needs.
We look forward to collaborating closely with Ypsomed to achieve our shared vision of improving patients' lives. Our Affinial platform and deep expertise in creating and operating regulated digital health solutions is a perfect fit with Ypsomed's drive for innovation and highest quality
says Jim O'Donoghue, President of S3 Connected Health.
The new product offering will be marketed through Ypsomed and will be offered to customers in collaboration with S3 Connected Health for customization to serve their specific use cases and brand.
Press release as PDF and images
Media Release Ypsomed partners with S3 Connected Health(68.1 KiB)
Cooperation S3 Connected Health and Ypsomed(1.4 MiB)
S3 Connected Health is the specialist digital health partner for life science companies, developing regulated digital health solutions that improve the lives of people with acute and chronic conditions. It has delivered award-winning, regulatory-compliant solutions across 20 therapy areas and in more than 50 countries. The company's scalable and secure solutions improve disease management, differentiate pharmaceutical products and deliver new therapeutic approaches. Affinial, S3 Connected Health's digital health platform, offers partners the opportunity to develop customised digital health solutions tailored to specific patient, device or disease needs. The platform's pre-built services can be customised and implemented with reduced costs and shorter time-to-market. www.s3connectedhealth.com
Ypsomed Holding AG published this content on 07 June 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 07 June 2023 05:05:04 UTC.
Ypsomed Holding AG is a Switzerland-based holding company engaged in the manufacture of injection pens for pharmaceutical and biotech companies. The Company develops and manufactures injection systems for custom-made self-administration, and markets pen needles for the treatment of diabetes, growth disorders or infertility, as well as therapeutic areas. The Company operates two business segments: Injection Systems and Diabetes Care. In the Injection Systems segment, the Company's YDS Ypsomed Delivery Systems offer a range of ready-to-use injection systems for pharmaceutical and biotech companies to administer of drugs or to develop and manufacture them in line with customer requirements. The Diabetes Care segment markets products such as pen needles or insulin pump to diabetics, doctors and health insurance providers. The Company operates its production sites in Burgdorf, Solothurn, Grenchen and Tabor, and sales and distribution network across Europe.
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
